Product Description: JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increasesthe expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1].
Applications: Cancer-programmed cell death
Formula: C19H19N5O4S
References: [1]Arts J, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97(10):1344-1353.
CAS Number: 604769-01-9
Molecular Weight: 413.45
Compound Purity: 99.05
Research Area: Cancer
Solubility: DMSO : 11.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;HDAC
Deutsch
English
